Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 15 June 2009, doi:10.1136/bmj.b2397
Cite this as: BMJ 2009;338:b2397
| The first 150 words of the full text of this article appear below. |
The paper by Jagsi et al in Cancer examining conflicts of interest in published clinical cancer research and reported by Tanne may be an example of classic confounding.1 2The industry funded trials may differ from non-industry funded trials in a way—for example, the treatments used—that is associated with the outcome. The treatments they compare are actually more effective.
The authors themselves note this, though not very clearly. Industry funded trials may not distort results at all (which is not the impression left in the readers mind after reading the BMJ), but they address different questions.
They may choose to investigate areas of cancer where success is likely to be greater. The questions they address and the designs of the studies may be different. This is bias, but of a very different nature to the idea that they distort results. The evidence is they tend to interpret similar results with
Stephen J Evans, professor of pharmacoepidemiology1
1 London School of Hygiene and Tropical Medicine, London WC1E 7HT
stephen.evans@lshtm.ac.uk